Bernd Froessler1,2, Ingo Weber1, Nicolette A Hodyl3, Khaschayar Saadat-Gilani1. 1. Department of Anaesthesia, Lyell McEwin Hospital, Elizabeth Vale, Australia. 2. Discipline of Acute Care Medicine, The University of Adelaide, Adelaide, Australia. 3. The Robinson Research Institute, School of Paediatric and Reproductive Health, The University of Adelaide, Adelaide, Australia.
Abstract
BACKGROUND: Cell salvage is a key part of patient blood management. Different techniques are available for salvaging blood. A new intra-operative autotransfusion filter system became available for reinfusion of unwashed whole blood. Concern exists regarding whether this technique induces coagulation disturbances, offsetting the benefits of the reinfusion of autologous blood. This study was designed to investigate the content of intra-operatively salvaged filtered blood and its impact after reinfusion on clot formation in patients undergoing primary hip arthroplasty. MATERIALS AND METHODS: Twenty-five patients scheduled for primary total hip arthroplasty were enrolled in the study. Cell salvage was performed using a new intra-operative autotransfusion filter system. Before surgery and within 1 hour of reinfusion of 300 mL or more of salvaged whole blood, blood samples were taken to assess clot formation by thromboelastometry and standard laboratory-based coagulation profiling. Cytokine content of the salvaged blood was assessed by enzyme-linked immunosorbent assays. RESULTS: Following reinfusion of 460 mL (median) of salvaged blood, thromboelastometry showed normal clot formation and did not indicate a coagulopathy. Clotting time, clot formation time, maximum firmness and maximum lysis all remained within the normal range. Standard laboratory coagulation tests were also normal in all patients before surgery and after reinfusion. Although monocyte chemoattractant protein-1 levels were higher than normal, all other measured cytokines were either undetectable or within the normal range. No adverse events were seen following cell salvage. DISCUSSION: Reinfusion of unwashed salvaged whole blood did not alter clot formation in our patients. The results add to the knowledge about this approach and contribute to the growing body of evidence regarding the lack of adverse events when reinfusing unwashed shed blood in major orthopaedic procedures.
BACKGROUND: Cell salvage is a key part of patient blood management. Different techniques are available for salvaging blood. A new intra-operative autotransfusion filter system became available for reinfusion of unwashed whole blood. Concern exists regarding whether this technique induces coagulation disturbances, offsetting the benefits of the reinfusion of autologous blood. This study was designed to investigate the content of intra-operatively salvaged filtered blood and its impact after reinfusion on clot formation in patients undergoing primary hip arthroplasty. MATERIALS AND METHODS: Twenty-five patients scheduled for primary total hip arthroplasty were enrolled in the study. Cell salvage was performed using a new intra-operative autotransfusion filter system. Before surgery and within 1 hour of reinfusion of 300 mL or more of salvaged whole blood, blood samples were taken to assess clot formation by thromboelastometry and standard laboratory-based coagulation profiling. Cytokine content of the salvaged blood was assessed by enzyme-linked immunosorbent assays. RESULTS: Following reinfusion of 460 mL (median) of salvaged blood, thromboelastometry showed normal clot formation and did not indicate a coagulopathy. Clotting time, clot formation time, maximum firmness and maximum lysis all remained within the normal range. Standard laboratory coagulation tests were also normal in all patients before surgery and after reinfusion. Although monocyte chemoattractant protein-1 levels were higher than normal, all other measured cytokines were either undetectable or within the normal range. No adverse events were seen following cell salvage. DISCUSSION: Reinfusion of unwashed salvaged whole blood did not alter clot formation in our patients. The results add to the knowledge about this approach and contribute to the growing body of evidence regarding the lack of adverse events when reinfusing unwashed shed blood in major orthopaedic procedures.
Authors: Santiago R Leal-Noval; Manuel Muñoz; Marisol Asuero; Enric Contreras; José A García-Erce; Juan V Llau; Victoria Moral; José A Páramo; Manuel Quintana Journal: Blood Transfus Date: 2013-06-17 Impact factor: 3.443
Authors: Wieger G Horstmann; Martzen J Swierstra; David Ohanis; Rob Rolink; Boudewijn J Kollen; Cees C P M Verheyen Journal: Int Orthop Date: 2014-01 Impact factor: 3.075
Authors: Kevin M Trentino; Shannon L Farmer; Stuart G Swain; Sally A Burrows; Axel Hofmann; Rinaldo Ienco; Warren Pavey; Frank F S Daly; Anton Van Niekerk; Steven A R Webb; Simon Towler; Michael F Leahy Journal: Transfusion Date: 2014-12-08 Impact factor: 3.157
Authors: N Islam; M Whitehouse; S Mehendale; M Hall; J Tierney; E O'Connell; A Blom; G Bannister; J Hinde; R Ceredig; B A Bradley Journal: Clin Exp Immunol Date: 2014-08 Impact factor: 4.330
Authors: Christiaan N Mamczak; Jacob Speybroeck; John E Stillson; Joseph Dynako; Andres Piscoya; Ethan E Peck; Michael Aboukhaled; Emily Cancel; Michael McDonald; Diego Garcia; John Lovejoy; Stephanie Lubin; Robert Stanton; Matthew E Kutcher Journal: J Clin Med Date: 2022-07-12 Impact factor: 4.964